Verismo Therapeutics Secures $28M From HLB Innovation Ahead of AACR 2026 Late-Breaking KIR-CAR Clinical Debut
Verismo Therapeutics announced a $28 million investment from HLB Innovation to accelerate clinical development of its KIR-CAR platform, timed to the company's first-ever presentation of SynKIR-110 Phase 1 (STAR-101) multi-chain KIR-CAR clinical data in the AACR 2026 Late-Breaking Clinical Trials plenary (April 20). Verismo is a Penn/Carl June spinout using a modified NK-cell-derived receptor and DAP12 pairing to improve T-cell persistence.